organization · Reporting owner

Newtyn Capital Partners, LP

Disclosed activity across 2 companies

Tapewire entity: 120666
SEC CIK: 0001789643

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770	See Remarks	January 12, 2023	January 17, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MERRIMACK PHARMACEUTICALS INC

Report date January 12, 2023 · Filed January 17, 2023

Jointly reported with Levy Noah G., Newtyn Management, LLC, NEWTYN PARTNERS, LP, NEWTYN TE PARTNERS, LP, Ledo Capital, LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,119,586	Reported balance After 2023-01-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-01-12 · Purchase · Acquired 100,000 · Balance 1,119,586 F1: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Garrett Motion Inc.

Report date April 30, 2021 · Filed May 04, 2021

Jointly reported with Newtyn Management, LLC, NEWTYN PARTNERS, LP, NEWTYN TE PARTNERS, LP, Ledo Capital, LLC, Levy Noah G.

Section 16 reporting ended · disclosed 2021-05-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2021-04-30 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-04-30 · Other · Disposed 1,802,095 · Balance 0 F1: On September 20, 2020, Garrett Motion Inc. (the "Issuer") and certain of its subsidiaries (collectively, the "Debtors") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On April 26, 2021, the Debtors filed an amended Chapter 11 plan of reorganization (the "Plan") and on April 9, 2021, the Issuer filed a supplement to the Plan (as amended on April 20, 2021 and April 22, 2021, the "Plan Supplement") with the Bankruptcy Court. On April 26, 2021, the Bankruptcy Court entered an order confirming the Plan (the "Confirmation Order") and, on April 30, 2021 (the "Effective Date") the conditions to effectiveness of the Plan were satisfied or waived and the Issuer emerged from bankruptcy. F2: (Continued from footnote 1) On the Effective Date, all outstanding shares of the Issuer's common stock outstanding prior to the Effective Date were canceled, released, and extinguished, and of no further force or effect and without any need for a holder of such common stock to take further action with respect thereto. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Persons with respect to the Issuer. F3: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly held 1,117,299 and 684,796 shares, respectively, of common stock of the Issuer. Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons."

Filing footnotes · ownership attribution and instrument terms

F1: On September 20, 2020, Garrett Motion Inc. (the "Issuer") and certain of its subsidiaries (collectively, the "Debtors") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On April 26, 2021, the Debtors filed an amended Chapter 11 plan of reorganization (the "Plan") and on April 9, 2021, the Issuer filed a supplement to the Plan (as amended on April 20, 2021 and April 22, 2021, the "Plan Supplement") with the Bankruptcy Court. On April 26, 2021, the Bankruptcy Court entered an order confirming the Plan (the "Confirmation Order") and, on April 30, 2021 (the "Effective Date") the conditions to effectiveness of the Plan were satisfied or waived and the Issuer emerged from bankruptcy.

F2: (Continued from footnote 1) On the Effective Date, all outstanding shares of the Issuer's common stock outstanding prior to the Effective Date were canceled, released, and extinguished, and of no further force or effect and without any need for a holder of such common stock to take further action with respect thereto. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Persons with respect to the Issuer.

F3: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly held 1,117,299 and 684,796 shares, respectively, of common stock of the Issuer. Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons."

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 12, 2023 Filed Jan 17, 2023 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	100,000	$11.90	$1,190,000.00	Disclosure SEC source: 0000899243-23-001838 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,119,586 F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 03, 2023 Filed Jan 4, 2023 16:06 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	5,300	$11.24	$59,563.52	Disclosure SEC source: 0000899243-23-000580 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,019,586 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.21 to $11.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
December 30, 2022 Filed Jan 4, 2023 16:06 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,300	$11.24	$14,614.99	Disclosure SEC source: 0000899243-23-000580 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,014,286 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.21 to $11.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 13, 2022 Filed Jul 15, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	3,095	$5.89	$18,226.76	Disclosure SEC source: 0000899243-22-026124 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 754,108 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.60 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 12, 2022 Filed Jul 13, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	2,816	$5.86	$16,515.56	Disclosure SEC source: 0000899243-22-026020 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 751,013 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.91 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	700	$5.97	$4,181.59	Disclosure SEC source: 0000899243-22-026020 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 748,197 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.905, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 08, 2022 Filed Jul 11, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,378	$5.99	$8,249.12	Disclosure SEC source: 0000899243-22-025909 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 747,497 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.945 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
July 07, 2022 Filed Jul 11, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,100	$5.99	$6,586.03	Disclosure SEC source: 0000899243-22-025909 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 746,119 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.93 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 30, 2022 Filed Jul 5, 2022 16:06 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,550	$5.76	$8,921.49	Disclosure SEC source: 0000899243-22-024972 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 745,019 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.635 to $5.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 24, 2022 Filed Jun 27, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,000	$5.99	$5,990.00	Disclosure SEC source: 0000899243-22-024187 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 743,469 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.95 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 23, 2022 Filed Jun 27, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	500	$6.00	$3,000.00	Disclosure SEC source: 0000899243-22-024187 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 742,469 F1 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 17, 2022 Filed Jun 21, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	385	$5.97	$2,298.14	Disclosure SEC source: 0000899243-22-023332 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 741,969 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 17, 2022 Filed Jun 21, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	515	$5.97	$3,074.14	Disclosure SEC source: 0000899243-22-023332 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,012,986 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 16, 2022 Filed Jun 21, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	223	$5.45	$1,214.90	Disclosure SEC source: 0000899243-22-023332 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 741,584 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $5.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 16, 2022 Filed Jun 21, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	297	$5.45	$1,618.06	Disclosure SEC source: 0000899243-22-023332 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,012,471 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.40 to $5.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 15, 2022 Filed Jun 16, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,241	$5.37	$6,659.08	Disclosure SEC source: 0000899243-22-022785 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 741,361 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 15, 2022 Filed Jun 16, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,659	$5.37	$8,902.03	Disclosure SEC source: 0000899243-22-022785 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,012,174 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 14, 2022 Filed Jun 16, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	8,961	$5.17	$46,357.94	Disclosure SEC source: 0000899243-22-022785 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 740,120 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 14, 2022 Filed Jun 16, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	11,977	$5.17	$61,960.61	Disclosure SEC source: 0000899243-22-022785 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,010,515 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 13, 2022 Filed Jun 14, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	4,151	$5.15	$21,372.67	Disclosure SEC source: 0000899243-22-022373 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 731,159 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.045 to $5.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 13, 2022 Filed Jun 14, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	5,548	$5.15	$28,565.54	Disclosure SEC source: 0000899243-22-022373 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 998,538 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.045 to $5.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 10, 2022 Filed Jun 14, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	2,733	$4.92	$13,448.00	Disclosure SEC source: 0000899243-22-022373 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 727,008 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
June 10, 2022 Filed Jun 14, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	3,653	$4.92	$17,974.95	Disclosure SEC source: 0000899243-22-022373 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 992,990 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.80 to $5.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 31, 2022 Filed Feb 1, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	523	$5.05	$2,640.78	Disclosure SEC source: 0000899243-22-003837 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 724,275 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.87 to $5.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 31, 2022 Filed Feb 1, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	714	$5.05	$3,605.20	Disclosure SEC source: 0000899243-22-003837 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 989,337 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.87 to $5.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 28, 2022 Filed Feb 1, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	11,458	$4.48	$51,295.17	Disclosure SEC source: 0000899243-22-003837 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 723,752 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 28, 2022 Filed Feb 1, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	1,505	$4.48	$6,737.58	Disclosure SEC source: 0000899243-22-003837 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 988,623 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.28 to $4.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 27, 2022 Filed Jan 28, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	16,272	$4.82	$78,474.97	Disclosure SEC source: 0000899243-22-003553 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 712,294 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.59 to $5.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 26, 2022 Filed Jan 28, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	19,528	$5.01	$97,784.51	Disclosure SEC source: 0000899243-22-003553 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 696,022 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 11, 2022 Filed Jan 12, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	14,728	$4.00	$58,884.02	Disclosure SEC source: 0000899243-22-001744 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 676,494 F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.78 to $4.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 11, 2022 Filed Jan 12, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	76,542	$4.00	$306,022.57	Disclosure SEC source: 0000899243-22-001744 · doc4.xml · nonDerivative · entry 3 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 987,118 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.78 to $4.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 10, 2022 Filed Jan 12, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	5,960	$3.83	$22,853.02	Disclosure SEC source: 0000899243-22-001744 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 661,766 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $3.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 10, 2022 Filed Jan 12, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	8,719	$3.83	$33,432.13	Disclosure SEC source: 0000899243-22-001744 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 910,576 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $3.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 07, 2022 Filed Jan 10, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	3,565	$3.82	$13,611.88	Disclosure SEC source: 0000899243-22-001470 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 655,806 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.75 to $3.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
January 07, 2022 Filed Jan 10, 2022 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	5,215	$3.82	$19,911.91	Disclosure SEC source: 0000899243-22-001470 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 901,857 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.75 to $3.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
April 30, 2021 Filed May 4, 2021 00:10 UTC	Garrett Motion Inc. GTX · Entity 1720	OtherCommon Stock	1,802,095	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-017876 · doc4.xml · nonDerivative · entry 1 Newtyn Management, LLC · CIK 0001569241 · Member of 10% owner group NEWTYN PARTNERS, LP · CIK 0001548707 · Member of 10% owner group NEWTYN TE PARTNERS, LP · CIK 0001548709 · Member of 10% owner group Newtyn Capital Partners, LP · CIK 0001789643 · Member of 10% owner group Ledo Capital, LLC · CIK 0001789647 · Member of 10% owner group Levy Noah G. · CIK 0001788608 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On September 20, 2020, Garrett Motion Inc. (the "Issuer") and certain of its subsidiaries (collectively, the "Debtors") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On April 26, 2021, the Debtors filed an amended Chapter 11 plan of reorganization (the "Plan") and on April 9, 2021, the Issuer filed a supplement to the Plan (as amended on April 20, 2021 and April 22, 2021, the "Plan Supplement") with the Bankruptcy Court. On April 26, 2021, the Bankruptcy Court entered an order confirming the Plan (the "Confirmation Order") and, on April 30, 2021 (the "Effective Date") the conditions to effectiveness of the Plan were satisfied or waived and the Issuer emerged from bankruptcy. F2 · kind: (Continued from footnote 1) On the Effective Date, all outstanding shares of the Issuer's common stock outstanding prior to the Effective Date were canceled, released, and extinguished, and of no further force or effect and without any need for a holder of such common stock to take further action with respect thereto. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Persons with respect to the Issuer. F1 · price: On September 20, 2020, Garrett Motion Inc. (the "Issuer") and certain of its subsidiaries (collectively, the "Debtors") each filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the Southern District of New York (the "Bankruptcy Court"). On April 26, 2021, the Debtors filed an amended Chapter 11 plan of reorganization (the "Plan") and on April 9, 2021, the Issuer filed a supplement to the Plan (as amended on April 20, 2021 and April 22, 2021, the "Plan Supplement") with the Bankruptcy Court. On April 26, 2021, the Bankruptcy Court entered an order confirming the Plan (the "Confirmation Order") and, on April 30, 2021 (the "Effective Date") the conditions to effectiveness of the Plan were satisfied or waived and the Issuer emerged from bankruptcy. F2 · price: (Continued from footnote 1) On the Effective Date, all outstanding shares of the Issuer's common stock outstanding prior to the Effective Date were canceled, released, and extinguished, and of no further force or effect and without any need for a holder of such common stock to take further action with respect thereto. Accordingly, this Form 4 shall constitute an exit filing for the Reporting Persons with respect to the Issuer. F3 · ownership.nature: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly held 1,117,299 and 684,796 shares, respectively, of common stock of the Issuer. Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons." Read SEC document
January 08, 2021 Filed Jan 12, 2021 02:10 UTC	Garrett Motion Inc. GTX · Entity 1720	PurchaseCommon Stock	62,846	$4.66	$293,050.90	Disclosure SEC source: 0000899243-21-001417 · doc4.xml · nonDerivative · entry 5 Newtyn Management, LLC · CIK 0001569241 · Member of 10% owner group NEWTYN PARTNERS, LP · CIK 0001548707 · Member of 10% owner group NEWTYN TE PARTNERS, LP · CIK 0001548709 · Member of 10% owner group Newtyn Capital Partners, LP · CIK 0001789643 · Member of 10% owner group Ledo Capital, LLC · CIK 0001789647 · Member of 10% owner group Levy Noah G. · CIK 0001788608 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,802,095 F1 · ownership.nature: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly hold 1,117,299 and 684,796 shares, respectively, of common stock of Garrett Motion Inc. (the "Company"). Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons." Read SEC document
January 07, 2021 Filed Jan 12, 2021 02:10 UTC	Garrett Motion Inc. GTX · Entity 1720	PurchaseCommon Stock	16,939	$4.73	$80,189.23	Disclosure SEC source: 0000899243-21-001417 · doc4.xml · nonDerivative · entry 4 Newtyn Management, LLC · CIK 0001569241 · Member of 10% owner group NEWTYN PARTNERS, LP · CIK 0001548707 · Member of 10% owner group NEWTYN TE PARTNERS, LP · CIK 0001548709 · Member of 10% owner group Newtyn Capital Partners, LP · CIK 0001789643 · Member of 10% owner group Ledo Capital, LLC · CIK 0001789647 · Member of 10% owner group Levy Noah G. · CIK 0001788608 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,739,249 F1 · ownership.nature: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly hold 1,117,299 and 684,796 shares, respectively, of common stock of Garrett Motion Inc. (the "Company"). Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons." Read SEC document
January 06, 2021 Filed Jan 12, 2021 02:10 UTC	Garrett Motion Inc. GTX · Entity 1720	PurchaseCommon Stock	67,310	$4.63	$311,577.99	Disclosure SEC source: 0000899243-21-001417 · doc4.xml · nonDerivative · entry 3 Newtyn Management, LLC · CIK 0001569241 · Member of 10% owner group NEWTYN PARTNERS, LP · CIK 0001548707 · Member of 10% owner group NEWTYN TE PARTNERS, LP · CIK 0001548709 · Member of 10% owner group Newtyn Capital Partners, LP · CIK 0001789643 · Member of 10% owner group Ledo Capital, LLC · CIK 0001789647 · Member of 10% owner group Levy Noah G. · CIK 0001788608 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,722,310 F1 · ownership.nature: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly hold 1,117,299 and 684,796 shares, respectively, of common stock of Garrett Motion Inc. (the "Company"). Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons." Read SEC document
January 04, 2021 Filed Jan 12, 2021 02:10 UTC	Garrett Motion Inc. GTX · Entity 1720	SaleCommon Stock	60,112	$4.40	$264,432.69	Disclosure SEC source: 0000899243-21-001417 · doc4.xml · nonDerivative · entry 2 Newtyn Management, LLC · CIK 0001569241 · Member of 10% owner group NEWTYN PARTNERS, LP · CIK 0001548707 · Member of 10% owner group NEWTYN TE PARTNERS, LP · CIK 0001548709 · Member of 10% owner group Newtyn Capital Partners, LP · CIK 0001789643 · Member of 10% owner group Ledo Capital, LLC · CIK 0001789647 · Member of 10% owner group Levy Noah G. · CIK 0001788608 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,655,000 F1 · ownership.nature: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly hold 1,117,299 and 684,796 shares, respectively, of common stock of Garrett Motion Inc. (the "Company"). Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons." Read SEC document
January 04, 2021 Filed Jan 12, 2021 02:10 UTC	Garrett Motion Inc. GTX · Entity 1720	PurchaseCommon Stock	60,112	$4.40	$264,613.02	Disclosure SEC source: 0000899243-21-001417 · doc4.xml · nonDerivative · entry 1 Newtyn Management, LLC · CIK 0001569241 · Member of 10% owner group NEWTYN PARTNERS, LP · CIK 0001548707 · Member of 10% owner group NEWTYN TE PARTNERS, LP · CIK 0001548709 · Member of 10% owner group Newtyn Capital Partners, LP · CIK 0001789643 · Member of 10% owner group Ledo Capital, LLC · CIK 0001789647 · Member of 10% owner group Levy Noah G. · CIK 0001788608 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,715,112 F1 · ownership.nature: Newtyn Partners, LP ("NP") and Newtyn TE Partners, LP ("NTE") directly hold 1,117,299 and 684,796 shares, respectively, of common stock of Garrett Motion Inc. (the "Company"). Newtyn Management, LLC ("NM") is the investment manager of NP and NTE. Newtyn Capital Partners, LP ("NCP") is the general partner to each of NP and NTE. Ledo Capital, LLC ("Ledo") is the general partner to NCP. Mr. Noah Levy is managing member to NM. NP, NTE, NM, NCP, Ledo and Mr. Levy are collectively referred to as the "Reporting Persons." Read SEC document
December 01, 2020 Filed Dec 3, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	12,417	$4.00	$49,656.82	Disclosure SEC source: 0000899243-20-032668 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 652,241 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.955 to $4.000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
December 01, 2020 Filed Dec 3, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	17,359	$4.00	$69,420.38	Disclosure SEC source: 0000899243-20-032668 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 896,642 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.955 to $4.000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
November 24, 2020 Filed Nov 27, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	28,809	$3.65	$105,152.85	Disclosure SEC source: 0000899243-20-032258 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 639,824 F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
November 24, 2020 Filed Nov 27, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	40,278	$3.65	$147,014.70	Disclosure SEC source: 0000899243-20-032258 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 879,283 F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
November 12, 2020 Filed Nov 16, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	23,556	$3.65	$85,863.98	Disclosure SEC source: 0000899243-20-031115 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 611,015 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.60 to $3.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
November 12, 2020 Filed Nov 16, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	32,934	$3.65	$120,047.72	Disclosure SEC source: 0000899243-20-031115 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 839,005 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.60 to $3.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
August 13, 2020 Filed Aug 17, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	254	$3.50	$889.00	Disclosure SEC source: 0000899243-20-022561 · doc4.xml · nonDerivative · entry 2 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 587,459 F2 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
August 13, 2020 Filed Aug 17, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	354	$3.50	$1,239.00	Disclosure SEC source: 0000899243-20-022561 · doc4.xml · nonDerivative · entry 1 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 806,071 F1 · ownership.nature: The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document
August 12, 2020 Filed Aug 13, 2020 16:05 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	PurchaseCommon Stock	834	$3.49	$2,913.16	Disclosure SEC source: 0000899243-20-022283 · doc4.xml · nonDerivative · entry 4 Levy Noah G. · CIK 0001788608 · Director · See remarks Newtyn Management, LLC · CIK 0001569241 · See Remarks NEWTYN PARTNERS, LP · CIK 0001548707 · See Remarks NEWTYN TE PARTNERS, LP · CIK 0001548709 · See Remarks Newtyn Capital Partners, LP · CIK 0001789643 · See Remarks Ledo Capital, LLC · CIK 0001789647 · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 587,205 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.45 to $3.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F4 · ownership.nature: The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.